Drugs / Momelotinib
Momelotinib
also known as
MMB · CYT-0387 · CYT-11387 · CYT-11387 DIHYDROCHLORIDE MONOHYDRATE · CYT-387 DIHYDROCHLORIDE · CYT-387 DIHYDROCHLORIDE MONOHYDRATE · CYT387 · GS-0387 · +5 more
Small molecule targets ACVR1, JAK1, JAK2, TBK1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Omjjara | — | 2024-01-25 | europa.eu ↗ |
| Approved | US (FDA) | OJJAARA | — | 2023-09-15 | fda.gov ↗ |
Trials 23 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04176198 Background | Dec 2019 → Apr 2027 expected | myelofibrosis | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07424950 Background | Nov 2026 → Nov 2028 expected | myelofibrosis | United Lincolnshire Hospitals NHS Trust | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05980806 Background | Apr 2024 → Jun 2027 expected | myelofibrosis, thrombocytopenia | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07498205 Comparator | Aug 2026 → Aug 2029 expected | myelofibrosis | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Momelotinib | “assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis” NCT03441113 ↗25“Momelotinib (MMB) tablet administered orally once daily” NCT02515630 ↗ “Momelotinib 200 mg QD alone” NCT07424950 ↗ |
| Known as | CYT-0387 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | CYT-11387 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | CYT-11387 DIHYDROCHLORIDE MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | CYT-387 DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | CYT-387 DIHYDROCHLORIDE MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | CYT387 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00935987 ↗ |
| Known as | GS-0387 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | MMB | “This study will evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of momelotinib (MMB) and erlotinib” NCT02206763 ↗4“assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis” NCT03441113 ↗ “Momelotinib (MMB) tablet(s) administered orally once or twice daily” NCT02244489 ↗ “Momelotinib (MMB) tablet administered orally once daily” NCT02515630 ↗ “Momelotinib (MMB)” NCT02258607 ↗ |
| Known as | MOMELOTINIB DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | Momelotinib hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | Ojjaara | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Known as | Omjjara | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078178 ↗ |
| Action | Inhibit | “Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2” PMID 27634203 ↗ Sep 2016 |
| Modality | Small molecule | “Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2” PMID 27634203 ↗ Sep 2016 |
| Route | Oral | “CYT387 will be orally self-administered as a single daily dose” NCT00935987 ↗ |
| Target | ACVR1 | “also inhibit activin A receptor type 1 (ACVR1)” PMID 37042865 ↗ Jul 2023 |
| Target | JAK1 | “inhibitor of Janus kinase 1 (JAK1)” PMID 37042865 ↗ Jul 2023 |
| Target | JAK2 | “inhibitor of Janus kinase 1 (JAK1) and JAK2” PMID 37042865 ↗ Jul 2023 |